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ABSTRACT 
 
Objectives: We aimed to identify and evaluate i) treatment-emergent adverse events (TEAE 
[worse or new since baseline]) and the sub-group of severe TEAEs in a placebo-controlled 
seven-day randomised trial of regular, low-dose, sustained-release oral morphine for chronic 
breathlessness, and ii) clinical characteristics associated with TEAE. 
Methods: Safety analysis of trial data. Adults with chronic breathlessness (modified Medical 
Research Council breathlessness score ≥2) due to heart or lung disease, or cancer, not on 
regular opioids were eligible. Symptoms associated with opioids (TEAE of special interest) 
were systematically sought using Common Terminology Criteria for Adverse Events 
(CTCAE) grading. Other harms could be reported at any time. The relationship between 
characteristics and presence of ≥1 TEAE of special interest was explored using univariable 
logistic regression analyses. 
Results: 1449/5624 (26%) AEs from 279 participants were TEAE of which 150/1449 (10%) 
were severe (CTCAE grades 3 -5). 1086/5624 (75%) were events of special interest of which 
41/1086 (4%) were severe. Compared with placebo, morphine was not associated with more 
TEAE or severe TEAE of special interest (TEAE: odds ratio 0.53, 95% CI 0.21 to 1.38, 
p=0.20; severe TEAE: odds ratio 0.96, 95% CI 0.27 to 3.41, p=0.95) nor with CTCAE 
severity grade (Χ2=4.39, p=0.50). Amongst the 26/150 (17%) with severe TEAEs, study 
withdrawal was more common in the morphine arm (18/26 [69%] morphine arm; 8/26 [30%] 
placebo arm). None of the severe TEAEs was a respiratory harm. 
Conclusions: Severe morphine-associated toxicity was uncommon and not associated with 
study arm. Clinical consequences were minor and self-limiting.  
  
 INTRODUCTION 
Morphine has been used for thousands of years as an analgesic and the profile of harms when 
used for pain, ranging from mild and self-limiting to serious and life-threatening, are well 
documented. The most common harms of all opioid medications are constipation almost 
universally and nausea, mainly as the medication is initiated. Both side-effects can be 
successfully managed for most people. Respiratory depression is the most feared 
consequence of opioids. Clinically, from first principles, best practice is that opioids are 
prescribed at the lowest dose possible aiming for adequate analgesia which allows 
improvement in function and quality of life.  
 
The evidence base is growing for the use of regular, low-dose (<30mg/day), sustained-release 
oral morphine [1] for people with chronic breathlessness (disabling breathlessness despite 
optimum treatment of the underlying cause),[2] with the most robust data being for patients 
with chronic obstructive pulmonary disease with a modified Medical Research Council 
(mMRC) breathlessness grade of 3 or 4.[3] This is reflected in the guidance issued by leading 
clinical bodies around the world,[4-8] and the recent extension of licence to include the 
indication of chronic breathlessness for Kapanol®, a sustained release morphine preparation, 
by the Therapeutic Goods Administration of Australia.[9]  
As the regular use of low-dose oral morphine may be considered for people with advanced 
cardio-respiratory disease and chronic breathlessness, most of whom already suffer from poor 
respiratory reserve, respiratory depression remains a major fear. It is a concern for clinicians 
prescribing morphine for the clinical indication of chronic breathlessness.[10] Patient 
resistance is also cited as a reason for non-prescription by professionals although evidence for 
this is largely lacking.[11] Patients’ opioid-fears are well known, particularly amongst people 
with cancer, and concerns about addiction, confusion and sedation are common.[12] 
However, patient experience of taking sustained-release morphine for chronic breathlessness 
in supported practice appears to be good.[13] One study found some patients’ concerns 
seemed to be prompted by the clinician.[14] Adding to this is the consistent and persistent 
medication authority warnings and contraindications in people with cardio-respiratory 
disease, well known by clinicians and spelled out in patient information sheets. Getting the 
balance right is important; to avoid overuse in the population while allowing needed and 
appropriate treatment of intractable symptoms in people with advanced life-limiting illness. 
Accurate information on risks and management of morphine-induced symptoms is important 
in patients’ and clinicians’ choices as to whether using the medication could provide net 
benefits. Data from randomised controlled trials (RCTs) in chronic breathlessness are limited. 
A key role for RCTs is to quantify directly-attributable harms in excess of those that would 
have been experienced without the intervention − treatment emergent adverse events 
(TEAE).[15] TEAEs are defined as symptoms that appear or worsen after baseline.[15] As 
the patient population in which opioids might be considered for chronic breathlessness have 
advanced disease, often with comorbidities and reduced performance status, such placebo-
controlled safety data are crucial.   
The primary aim of this study was to identify TEAE data collected in a placebo-controlled 
phase III RCT of sustained-release (SR) morphine for chronic breathlessness and to evaluate 
if these are more common or more severe in the morphine compared with the placebo arm. 
The secondary aim was to identify clinical characteristics associated with TEAE (including 
allocation to morphine arm) in this study population. Effectiveness data and descriptive 
TEAE are reported elsewhere.[16]  
 
METHODS 
Participants and safety data collection 
This was a parallel group, multi-centre, double-blind, placebo-controlled, fixed-dose 
randomised (1:1) seven day trial of 20 mg once daily oral SR morphine and laxative, and 
matched blinded study drug and laxative (ACTRN126000806268).   Immediate-release 
morphine for breathlessness could also be taken “as needed” in 4-hourly 2.5mg doses in both 
arms. Participants were adults, not on regular opioids, with a modified Medical Research 
Council (mMRC) breathlessness score ≥2 at screening despite optimal treatment of their 
medical condition causing breathlessness 2 (heart or lung disease, or cancer) with no 
contraindications to morphine. People with moderate renal impairment or worse (calculated 
GFR ≤25mls/min), poor performance status (≤30 on the Australia-modified Karnofsky 
Performance Status [AKPS]),[17] or increased liver function tests (enzymes 3 x upper limit 
of normal) were excluded.  
Harms were sought prospectively and systematically during the 7 days’ treatment and for the 
four following weeks. Assessment was conducted by the study nurse at baseline, during the 
treatment week and then weekly post-treatment via telephone calls for four weeks. 
Ethics approval was obtained by all participating sites and the trial was registered 
(ACTRN126000806268) before first enrolment at any site. All participants provided written, 
informed consent. The trial was reported in accordance with the Consolidated Standards of 
Reporting Trials (CONSORT) statement.[18]  
Outcomes 
A daily patient diary specifically sought symptoms that may be associated with opioids 
(anxiety, appetite, concentration, confusion, constipation, nausea or vomiting, sleepiness and 
reduced well-being) and the National Institutes of Health NCI CTCAE version 4.0 Likert 
grades adverse events were used for ad hoc reporting.[19] Any adverse event recorded was 
counted as a TEAE if it appeared or worsened after baseline (noting high baseline symptom 
burdens for all symptoms of interest). A TEAE with a CTCAE grade of ≥3, or otherwise 
reported as a Serious Adverse Event as part of trial pharmacovigilance reporting, was 
categorised as a severe TEAE.  
The potentially opioid-related symptoms in the patient diary were identified a priori from the 
literature and collected in the trial as TEAEs of special interest together with any other harms 
reported. Of note, respiratory harms were assessed using pulse oximetry, end-tidal CO2, 
respiratory rate and SAE clinical reports. The outcome of the TEAE was noted 
(recovered/resolved; recovering/resolving; not recovered/resolved; recovered/resolved with 
sequelae) and whether or not it was accompanied by study participant withdrawal. 
Statistical analyses 
Outcomes were compared between study groups (morphine or placebo) using chi squared and 
t-tests as appropriate. 
In order to explore potential clinical predictors of TEAEs of special interest, a dependent 
variable was created (to indicate whether a participant experienced at least one TEAE of 
special interest during the reporting period) and associations for biologically plausible 
explanatory variables at baseline were explored using univariable logistic regression. 
Explanatory variables included: study arm, sex, age: end-tidal carbon dioxide (EtCO2) levels; 
AKPS,[17] body mass index (BMI), Charlson Comorbidity Index (CCI),[20] mMRC,[21] 
and renal function (creatinine clearance). Explanatory variables with evidence of statistically 
significant association with the dependent variable (assessed at p<0.10) were explored in a 
multiple logistic regression model in this exploratory study. This analysis was also repeated 
with at least one severe TEAE of special interest as the dependent variable. 
 
RESULTS 
Fourteen study sites randomised 284 participants to morphine (n=145) or placebo (n=139) 
between 2010 and 2015. The 284 patients had a mean age of 74.3 years (SD 9.3); 180 (63%) 
were male; 164 (58%) had COPD; and 167 (59%) had a baseline mMRC score of 3 or 4. The 
median AKPS was 60 (interquartile range [IQR] 50 to 70) and the median CCI Score was 3 
(IQR 1 to 4).  Baseline characteristics were comparable (see Table 1). Five participants (three 
in the morphine group and two in the placebo group) did not receive study medication and 
were not included in this safety dataset resulting in a population of 279 participants (142 in 
the morphine group and 137 in the placebo group). 
Table 1: Characteristics of participants in a multi-site, placebo-controlled, parallel arm, 
fixed dose study of 20mg sustained morphine daily for chronic breathlessness 
 Intention-to-treat – whole 
population 
Morphine 
(n=145) 
Placebo (n=139) 
Age (years); mean (SD) 74.0 (9.6) 74.5 (9.1) 
Sex; n (%) Female 52 (35.9%) 52 (37.4%) 
Performance status (AKPS); mean (SD) 60.8 (11.5) 61.5 (9.5) 
BMI (kg/m2); mean (SD) 25.2 (7.6) 25.9 (7.0) 
Clinician-rated mMRC 
breathlessness now score at 
eligibility n (%) 
2 13 (9%) 12 (8.6%) 
3 73 (50.3%) 69 (49.6%) 
4 59 (40.7%) 58 (41.7%) 
Baseline mean (SD) 
breathlessness scores (0-100mm 
visual analogue scale (VAS)); 
mean (SD) 
now 40.9 (22.0) 42.9 (23.1) 
worst 58.5 (23.8) 60.7 (24.9) 
average 
41.2 (18.5) 43.8 (20.6) 
Charlson Co-morbidity Index; median (range) 3.00 (0.0, 12.0) 2.00 (1.0, 13.0) 
Pulse oximetry SpO2 (%); mean (SD) 92.60 (4.17) 92.96 (4.46) 
End-tidal CO2 (mmHg); mean (SD) 27.41 (8.29) 25.53 (6.98) 
Primary cause for breathlessness; 
n (%) 
COPD 82  (56.6%) 82  (59.0%) 
Cancer 26  (17.9%) 22  (15.8%) 
Cardiac 
failure 
2   (1.4%) 2   (1.4%) 
Mixed 18  (12.4%) 19  (13.7%) 
Other  17  (11.7%) 14  (10.1%) 
Oxygen use; n (%) Yes  n (%) 87 (60.0%) 75 (54.0%) 
Smoking status; n (%) 
Never 
smoked 
24  (16.6%) 26  (18.7%) 
Ex-smoker 104  (71.7%) 95  (68.3%) 
Current 
smoker 
17  (11.7%) 16  (11.5%) 
Abbreviations: AKPS – Australia-modified Karnofsky Performance Status; BMI body mass 
index; CO2 carbon dioxide; COPD – chronic obstructive pulmonary disease; mMRC modified 
Medical Research Council breathlessness score. 
Morphine dose by arm 
Table 2 presents summaries of daily, total and average morphine use (mgs) for the morphine 
and placebo groups, and overall.  This accounts for the active treatment, of 20mg a day when 
taken, for the morphine group plus "as needed" 2.5mg doses of immediate-release morphine 
for both groups.  On average, per day, patients in the morphine group took 22.5mg (SD 3.3) 
of morphine, whilst the placebo group took 3.6mg (SD 3.8) which was all “as needed”.  
Figure 1 shows the change in average dose used by study arm over the 7 days. The average 
daily dose is lower when missing data are assumed to be 0mg (morphine group: mean 16.6, 
SD 7.9; placebo group: mean 2.9, SD 3.3). 
 
 Table 2. Morphine use by study arm 
Morphine use, mg Morphine (n=145) Placebo (n=139) Total (n=284) 
 
excludes missing 
data 
assumes missing 
data are 0mg 
excludes missing 
data 
assumes missing 
data are 0mg 
excludes missing 
data 
assumes missing 
data are 0mg 
Day 1 
22.0 (3.3) 18.8 (8.3) 2.7 (4.1) 2.4 (3.9) 12.3 (10.3) 10.8 (10.5) 
20.0 (20.0, 40.0) 20.0 (0.0, 40.0) 0.0 (0.0, 30.0) 0.0 (0.0, 30.0) 20.0 (0.0, 40.0) 7.5 (0.0, 40.0) 
Day 2 
22.5 (3.8) 19.2 (8.7) 3.4 (3.9) 2.9 (3.8) 13.2 (10.3) 11.2 (10.6) 
20.0 (20.0, 40.0) 20.0 (0.0, 40.0) 2.5 (0.0, 15.0) 0.0 (0.0, 15.0) 20.0 (0.0, 40.0) 7.5 (0.0, 40.0) 
Day 3 
22.8 (3.9) 18.2 (9.8) 3.6 (3.9) 3.1 (3.9) 13.1 (10.4) 10.8 (10.6) 
20.0 (20.0, 40.0) 20.0 (0.0, 40.0) 2.5 (0.0, 15.0) 2.5 (0.0, 15.0) 12.5 (0.0, 40.0) 7.5 (0.0, 40.0) 
Day 4 
22.7 (4.1) 17.5 (10.2) 4.1 (4.4) 3.5 (4.3) 13.2 (10.2) 10.7 (10.6) 
20.0 (20.0, 40.0) 20.0 (0.0, 40.0) 2.5 (0.0, 17.5) 2.5 (0.0, 17.5) 15.0 (0.0, 40.0) 7.5 (0.0, 40.0) 
Day 5 
22.8 (4.1) 17.1 (10.5) 4.1 (4.6) 3.4 (4.5) 13.2 (10.3) 10.4 (10.6) 
20.0 (20.0, 40.0) 20.0 (0.0, 40.0) 2.5 (0.0, 22.5) 2.5 (0.0, 22.5) 15.0 (0.0, 40.0) 5.0 (0.0, 40.0) 
Day 6 
22.7 (4.0) 16.8 (10.6) 4.2 (4.7) 3.6 (4.6) 12.9 (10.3) 10.3 (10.5) 
20.0 (20.0, 42.5) 20.0 (0.0, 42.5) 2.5 (0.0, 25.0) 2.5 (0.0, 25.0) 12.5 (0.0, 42.5) 5.0 (0.0, 42.5) 
Day 7 
22.2 (2.8) 8.6 (11.0) 3.7 (4.4) 1.7 (3.5) 12.3 (10.0) 5.2 (8.9) 
20.0 (20.0, 30.0) 0.0 (0.0, 30.0) 2.5 (0.0, 20.0) 0.0 (0.0, 20.0) 11.3 (0.0, 30.0) 0.0 (0.0, 30.0) 
Total 
116.2 (55.2) 116.2 (55.2) 20.6 (23.3) 20.6 (23.3) 69.4 (64.1) 69.4 (64.1) 
130.0 (0.0, 227.5) 130.0 (0.0, 227.5) 12.5 (0.0, 107.5) 12.5 (0.0, 107.5) 46.3 (0.0, 227.5) 46.3 (0.0, 227.5) 
Average per day 
22.5 (3.3) 16.6 (7.9) 3.6 (3.8) 2.9 (3.3) 13.0 (10.1) 9.9 (9.2) 
21.3 (20.0, 37.5) 18.6 (0.0, 32.5) 2.9 (0.0, 16.7) 1.8 (0.0, 15.4) 16.7 (0.0, 37.5) 6.6 (0.0, 32.5) 
Figures are mean (SD), median (maximum, maximum): For some participants, their morphine use data were missing for a particular day. For each treatment 
group, the first column excludes missing data and the second columns assumes missing data are zero 
Treatment Emergent Adverse Events (worse or new since baseline) by mean morphine use 
Overall, 5624 adverse events were recorded, of which 1449 (26%) were TEAEs; 767 TEAEs 
for 138 (97%) of the participants in the morphine groups, and 683 TEAEs for 132 (96%) of 
the participants in the placebo group.  Ten percent of the TEAEs (n=150) were severe; 
CTCAE grade 3-5 (Table 3) (69 for 38 participants in the morphine group, and 81 for 39 
participants in the placebo group).  A chi-squared test indicates there is no evidence of an 
association between treatment group and CTCAE grade (Χ2=4.39, p=0.50). 
Table 3. CTCAE grades for TEAEs by study group, n (%). 
CTCAE 
grade 
TEAEs in Morphine 
Group 
(n=767) 
TEAEs in Placebo Group 
(n=683) 
Total 
(n=1449) 
1 468 (61.0) 398 (58.4) 866 (59.8) 
2 227 (29.6) 201 (29.5) 428 (29.5) 
3 54 (7.0) 59 (8.7) 113 (7.8) 
4 8 (1.0) 14 (2.1) 22 (1.5) 
5 7 (0.9) 8 (1.2) 15 (1.0) 
Ungraded 3 (0.4) 2 (0.3) 5 (0.4) 
CTCAE, Common Terminology Criteria for Adverse Events; TEAE, Treatment Emergent 
Adverse Event. At least one TEAE reported for 139 participants in the morphine group and 
132 in the placebo group. 
Individual symptom/respiratory harm details are presented elsewhere.[16] Participants in the 
morphine group reported more constipation (56% vs 43%; p=0.037) and vomiting (37% vs 
23%; p=0.012). There was no statistically or clinically significant differences in mean change 
from baseline any measurement of respiratory harm in either arm.[16] 
 
Twenty-six severe TEAEs (17%) resulted in study withdrawal (18 [69%] from the morphine 
arm, and 8 [30%] from the placebo arm). The reported outcomes of the severe TEAEs are 
reported in Table 4. Of note, none of these related to respiratory harms.  
 
Table 4. Severe TEAE outcomes 
Outcome Withdrew from study, n (%) Remained in study, n (%) 
 Placebo 
(n=8) 
Morphine 
(n=17) 
Total 
(n=25) 
Placebo 
(n=73) 
Morphine 
(n=52) 
Total 
(n=125) 
Resolved 1 (12.5) 1 (5.9) 2 (8.0) 7 (9.6) 3 (5.8) 10 (8.0) 
Resolving 1 (12.5) 4 (23.5) 5 (20.0) 18 (24.7) 15 (28.9) 33 (26.4) 
Unresolved 5 (62.5) 6 (35.3) 11 
(44.0) 
8 (11.0) 7 (13.5) 15 (12.0) 
Resolved 
with 
sequelae 
0 (0.0) 1 (5.9) 1 (4.0) 1 (1.4) 3 (5.8) 4 (3.2) 
Not reported 1 (12.5) 5 (29.4) 6 (24.0) 39 (53.4) 24 (46.2) 63 (50.4) 
 
Treatment Emergent Adverse Events of special interest 
Among the 1449 TEAEs, 1086 (75%) were events of special interest (morphine 583/767 
[76%]; placebo 503/682 [74%]).  Two hundred and fifty nine participants (93%) had at least 
one TEAE of special interest (129 (91%) in the morphine group, and 130 (95%) in the 
placebo group).  Forty-one (4%) of the special interest TEAEs were graded 3-5 (16 events for 
11 participants in the morphine group, and 25 events for 16 participants in the placebo 
group).  
Predictors of TEAE of special interest 
Table 5 presents the results of the logistic regression analyses for special interest TEAEs (all 
and severe). 
Among the evaluated predictors, only sex was related with the risk of severe TEAEs; women 
were more likely to have a severe TEAE of special interest (OR 4.27, 95% CI 1.08 to 16.91, 
p=0.04). Treatment arm was not related (OR 0.96, 95% CI 0.27 to 3.41, p=0.95. 
In view of the lack of associated explanatory variables, multiple regression was not 
performed in this exploratory study. 
 
Table 5. Univariable analyses to predict likelihood of developing a (severe) TEAE of 
special interest with baseline factors 
 TEAE of special interest  Severe TEAE of special interest 
Variable 
(reference 
group for 
categorical 
data) 
Odds 
Ratio 
Standar
d error 
95% CI P 
value 
Odds 
Ratio 
Standar
d error 
95% CI P value 
Sex (male) 
n=279 
2.43 1.40 0.79 to 7.49 0.12 4.27 3.00 1.08 to 16.91 0.04 
Age, years 
n=276 
1.02 0.02 0.98 to 1.07 0.34 1.07 0.05 0.98 to 1.17 0.12 
Treatment 
group 
(placebo) 
n=279 
0.53 0.26 0.21 to 1.38 0.20 0.96 0.62 0.27 to 3.41 0.95 
EtCO2 
n=253  
0.98 0.03 0.92 to 1.04 0.49 1.05 0.05 0.97 to 1.15 0.23 
AKPS 
n=279 
1.02 0.02 0.98 to 1.07 0.26 0.97 0.03 0.92 to 1.03 0.33 
CCI 
n=276 
1.05 0.11 0.86 to 1.28 0.64 0.96 0.13 0.74 to 1.26 0.80 
mMRCa  
Grade 2 
Grade 3a 
Grade 4a 
n=243 
 
1.59 
0.34 
0.40 
 
2.27 
0.37 
0.43 
 
0.10 to 
26.36 
0.04 to 2.95 
0.05 to 3.34 
 
0.75 
0.33 
0.40 
 
* 
* 
* 
   
BMI 
n=266 
1.08 0.05 0.99 to 1.17 0.09 1.03 0.04 0.95 to 1.11 0.46 
Creatinine 
Clearance 
n=279 
1.00 0.01 0.99 to 1.01 0.98 0.98 0.01 0.95 to 1.01 0.15 
* insufficient data for analysis; EtCO2 end tidal carbon dioxide; AKPS Australian-modified 
Karnofsky Performace Status; CCI Charlson Comorbidity Index; mMRC modified Medical 
Research Council breathlessness scale; BMI body mass index. 
a reference group mMRC=1 
 
 
DISCUSSION 
People with chronic breathlessness due to advanced cardio-respiratory disease or cancer 
experience a large number of symptoms and have an underlying high risk of deterioration. In 
this study, 279 participants reported 5624 adverse events but only a quarter of these 
developed de novo or worsened from baseline and thus are of relevance in this placebo-
controlled trial of oral morphine. Fewer than one in twenty experienced a severe event of 
special interest and none was a respiratory harm. Of particular note, morphine was not related 
to either TEAE or severe TEAE in this study population. There were no baseline clinico-
demographic predictors of TEAEs or severe TEAE other than the indication that being a 
woman marginally increased the risk. Notably, renal function, comorbidity and performance 
status were not associated despite significant impairment of these variables in many of the 
trial population. 
Interestingly, even though no relationship between severe TEAE and morphine was 
demonstrated, for those where a severe TEAE led to trial withdrawal, this was more likely in 
the morphine arm. This may indicate that despite rigorous, objective measures of harms, there 
may be a qualitative aspect which is not captured in these data and which contributes to 
withdrawal. 
This study highlights the crucial importance of placebo-controlled trials for interventions 
where the evidence base for net-benefit is still developing and in patient populations with 
advanced disease with such high baseline burden of symptom. Further, there is evidence of 
investigator bias in adverse event attribution in favour of disease progression rather than the 
intervention that has been introduced.[22] This effectiveness study had inclusive eligibility 
criteria reflecting the patient population for whom morphine is already being prescribed in 
much of the world to reduce the symptomatic burden of chronic breathlessness.[23, 24]  
There were no instances of severe respiratory harms in this phase III study over seven days, 
where morphine was given to patients who were not on regular opioid treatment.[11] The 
lack of respiratory harms is consistent with a recent systematic review and meta-analysis of 
1064 patients from 67 studies with a range of study designs.[25] In one subgroup analysis 
there was a statistically significant increase in partial pressure of carbon dioxide and an 
insignificant reduction of partial pressure of oxygen and oxygen saturation, but the changes 
were clinically irrelevant. Only four participants had (non-serious) respiratory depression 
(variably defined, or not at all) and only one required temporary ventilator assistance for a 
reduced respiratory rate. This occurred after administration of 4 mg nebulized morphine for 
breakthrough breathlessness in a patient taking 30 mg oral slow-release morphine per day 
and 10 mg oral immediate release morphine when required for cancer-related pain.[26]  
  
Limitations 
These are short-term data of treatment over seven days, with follow up for the 4 weeks post-
treatment. However, they explore harms to patients at the time they are at most risk, that is, at 
dose initiation. Once at steady state, unless the dose increases or some other factor such as 
deterioration in renal function occurs, then one would not expect further TEAEs. Longer-term 
open label observational data (median 142 days, range 1 – 662 days) have been reported 
previously and are consistent with these findings,[27] however, in view of the benefit of 
placebo-controlled measures, ongoing trials have longer follow up (BEAMS, 
NCT02720822;[28] MORDYC, NCT02429050[29]).  This current study is unable to inform 
regarding longer-term problems with abuse or harms in relation to hormone or immune 
status, although the formulation used (sustained release morphine sulphate) is one least likely 
to be associated with abuse[30] or overdose related deaths.[31]  
The allowed use of immediate release morphine for “as needed” use in both arms may have 
led to an underestimation of a toxicity difference between the two arms. However, the 
average 24 hour dose in the placebo group was less than 5mg, which given morphine’s oral 
bioavailability (10 to 50%) is unlikely to be responsible for significant adverse events. 
Even though none of the variables showed a statistically significant signal at univariable 
analysis, we could have built a model using variables with a plausible explanation for 
association. However, we deemed in this exploratory study we should be cautious about the 
risks of over-interpretation. 
Strengths 
This study includes more participants than those from all included studies the most recent 
systematic review put together (n=279 compared with n = 198).[1] This study was 
prospective, multi-site, blinded, placebo-controlled, had broad (effectiveness) eligibility 
criteria and used standard measures so the natural history of the underlying disease(s) could 
be defined and causality attributed. There was frequent contact with participants and TEAE 
were systematically sought. 
Clinical implications 
Clinicians can treat chronically breathless opioid-naïve patients confidently with this starting 
dose of regular, low-dose, oral sustained release morphine in the context of careful patient 
selection and ongoing appropriate monitoring.  The absence of an identified sub-group at 
greater risk of harms gives further confidence in the careful use of this drug in this 
formulation. However, it is notable that twice as many participants with severe TEAE in the 
morphine arm withdrew from the study than in the placebo arm, although the absolute 
numbers are small. Although we found no association by study arm, it is good practice to 
assess and manage morphine-related harms such as constipation rigorously and expertly from 
morphine initiation. Failure to do so may reduce net-benefit even in those who continue on 
morphine because they are experiencing symptomatic improvement in their chronic 
breathlessness.[32]  
Research implications 
Conservative lower limits of renal function were used as an eligibility criterion but no TEAE 
harms relating to renal dysfunction were seen. Further work is needed to understand the safe 
lowest level of glomerular filtration rate in order to avoid limiting this therapy unnecessarily 
to people who may benefit. We do not know if patients with an initial response would gain 
further net-benefit by upward titration. A blinded dose titration placebo-controlled 
randomised trial is currently recruiting with a starting dose of 8mg/24hours sustained release 
morphine.[28]   
 
CONCLUSION 
Low-dose sustained release oral morphine appeared to be safe in this placebo-controlled trial. 
Only one quarter of adverse events were treatment emergent (developed de novo or worsened 
from baseline). Severe events of special interest were uncommon and clinical consequences 
were minor and self-limiting. Of note, none was a respiratory harm. Morphine was not related 
to either TEAE or severe TEAE in this study population. Although there was no excess 
TEAEs ≥2, more participants withdrew from study drug in the intervention arm highlighting 
the importance of meticulous prospective management of side-effects.  
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Figure 1. Mean daily morphine dose over time by study arm 
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